FUNDAMENTALS · Fundamentals · US Healthcare

Strata Critical Medical (SRTA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Strata Critical Medical (SRTA) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of $442M, trading at $5.11 on the NASDAQ. This SniperIQ fundamentals page covers Strata Critical Medical's valuation, profitability (net margin 18.5%), revenue (

97M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$442M
Net Margin18.5%
Revenue (FY25)
97M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Strata Critical Medical's market cap?

Strata Critical Medical (SRTA) has a market capitalization of approximately $442M, trading at $5.11 on the NASDAQ. Market cap moves with the live share price.

What is Strata Critical Medical's P/E ratio?

Strata Critical Medical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Strata Critical Medical?

Strata Critical Medical runs a net profit margin of 18.5%, a gross margin of 21.7%, and an operating margin of -7.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Strata Critical Medical generate?

Strata Critical Medical reported revenue of

97M for fiscal year 2025, with net income of $41M and earnings per share (EPS) of -0.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Strata Critical Medical pay a dividend?

Strata Critical Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Strata Critical Medical financially healthy?

Strata Critical Medical carries a debt-to-equity ratio of 0.02x and a current ratio of 5.93x, with a market beta of 2.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Strata Critical Medical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Strata Critical Medical (SRTA) the key facts are: market cap $442M, revenue

97M, 52-week range 3.675-6.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Strata Critical Medical's full fundamentals live

Get Strata Critical Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Cabaletta Bio (CABA) fundamentals · Oceania Healthcare (OCA) fundamentals · Community Health Systems (CYH) fundamentals · Naba Alsaha Medical Services (9546) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons